Primary objective:
To compare radiographic progression-free survival (rPFS) and overall survival (OS) with enzalutamide and rucaparib versus enzalutamide alone for patients with metastatic castration resistant prostate cancer commencing first-line therapy.
Secondary objectives:
In patients commencing enzalutamide as the first-line therapy for metastatic castration resistant prostate cancer, to evaluate the effects of concurrent administration of rucaparib on:
- rPFS and OS within HRR mutant and wild-type patients
- Time to unequivocal clinical progression
- Best radiographic response using prostate cancer working group 3 (PCWG3) criteria
- Duration of overall response
- PSA response rate
- Best response by serum PSA by months 7 and 13 using categorical and continuous measures.
- Time to first symptomatic skeletal event (SSE)
- Safety and tolerability as measured by NCI Common Toxicity Criteria; trial discontinuation for treatment emergent toxicities
Inclusion Criteria:
- Histologic/cytologic documentation of prostate adenocarcinoma
- Adequate archival tumor specimen or archival slides
- Progressive disease must be demonstrated at study entry while the patient is on continuous androgen deprivation therapy (ADT) or status post orchiectomy
- Measurable or non-measurable metastatic disease
- No prior therapy for metastatic castration-resistant prostate cancer
- >= 2 weeks or 5 half-lives (whichever is shorter) since prior therapy
- No prior therapy with enzalutamide, rucaparib or any other PARP inhibitor, or platinum chemotherapy
- Prior docetaxel and/or novel anti-androgen use is allowed only if given in the hormone-sensitive non-metastatic or metastatic, or castration-resistant non-metastatic disease setting
- Patient must have discontinued all previous treatments for cancer (except ADT and bone anti-responsive therapies such as denosumab or zoledronic acid)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Normal lab values
- No clinically suspected central nervous system (CNS) (leptomeningeal or parenchymal) metastases
- No known or suspected history of cytopenia
- No blood product transfusion, granulocyte/granulocyte-macrophage-colony stimulating factor (G-CSF/GM-CSF), or erythropoietin/thrombopoietin use within 14 days of pre-registration
- No significant cardiac history
- No history of seizure or any condition that may increase the patient's seizure risk within 2 years
- Other inclusion/exclusion criteria are present. Please contact the study team for a complete list.
Sponsor(s)
Alliance
Principal Investigator(s)
Faysal Haroun, MD
Request Information